Get the latest Science News and Discoveries

BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Syndrome shows promising results in Phase II clinical trials | Proteins and Peptides

None

Related news:

Expand the UK's COVID-19 symptom list to prevent cases being missed, say experts

Cats may catch COVID-19 from sleeping on their owner's bed

Final Trial Results Confirm Disappointment on CureVac Vaccine